Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.

Pediatr Allergy Immunol 2016 08 18;27(5):446-51. Epub 2016 May 18.

Genomics Research Center, Taipei, Taiwan.

Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcεRI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti-IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others. Anti-CεmX, which binds to membrane-bound IgE (mIgE) on IgE-switched B cells, lyses mIgE-expressing B lymphoblasts and prevents the allergen-induced generation of IgE-producing plasma cells, offers an alternative mechanism of intervening with the IgE inflammatory pathway. Because anti-CεmX does not bind to free IgE, it can modulate the IgE pathway regardless of the serum IgE levels in treated patients. These unique pharmacologic mechanisms potentially enable anti-CεmX to provide different clinical utilities from anti-IgE and serve as a therapeutic and a prophylactic in some IgE-mediated diseases, which are not adequately treated with current medicine.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pai.12584DOI Listing
August 2016
38 Reads

Publication Analysis

Top Keywords

ige-mediated diseases
12
ige pathway
8
ige
8
free ige
8
treating ige-mediated
8
reported allergic
4
anti-ige reported
4
bronchopulmonary aspergillosis
4
anti-cεmx provide
4
plasma cells
4
allergic rhinitis
4
allergic bronchopulmonary
4
ige-producing plasma
4
efficacy anti-ige
4
rhinitis allergic
4
enable anti-cεmx
4
provide clinical
4
clinical utilities
4
chronic spontaneous
4
asthma chronic
4

References

(Supplied by CrossRef)
Tailored therapy for severe asthma
Menzella et al.
Multidiscip Respir Med 2015
The potential of biologics for the treatment of asthma
Pelaia et al.
Nat Rev Drug Discov 2012
Identification of gamma-E-antibodies as a carrier of reaginic activity
Ishizaka et al.
J Immunol 1967
Immunological studies of an atypical (myeloma) immunoglobulin
Johansson et al.
Immunology 1967
The pharmacological basis of anti-IgE therapy
Chang et al.
Nat Biotechnol 2000

Similar Publications